Dogwood Therapeutics, Inc.
DWTX evidence brief
What we can confirm
- BioSniper Score:
- 8.5 / 10
- Market Cap:
- $65.9M
- Lead Asset:
- halneuron (Phase 2)
What it means
What to watch
Prepared research question
What matters most for DWTX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · DWTX
Dogwood Therapeutics (DWTX) is a pre-revenue, development-stage biopharmaceutical company focused on developing non-opioid medicines for pain and peripheral neuropathy associated with cancer treatment, with lead asset Halneuron® in Phase 2b and SP16 entering Phase 1.
Key risk: Pre-revenue status
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Market Cap
$65.9M
Cash Runway
—
Lead Asset
halneuron (Phase 2)
Next Catalyst
—
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 1 clinical trial for Dogwood Therapeutics, Inc..
Dogwood Therapeutics (DWTX) is a pre-revenue, development-stage biopharmaceutical company focused on developing non-opioid medicines for pain and peripheral neuropathy associated with cancer treatment, with lead asset Halneuron® in Phase 2b and SP16 entering Phase 1.
- Pre-revenue, development-stage biopharmaceutical company focused on pain and peripheral neuropathy from cancer treatment [sec_mda · as of 2026-08-14].
- Cash & equivalents $9.6M as of 2026-06-30 [sec].
- Net income -$11.5M for the period ending 2026-06-30 [sec].
- Shareholders' equity $68.4M as of 2026-06-30 [sec].
- Halneuron® Phase 2b trial completed enrollment of 239 patients; top-line data expected November 2026 [news · published 2026-09-14].
What works
- Halneuron® has FDA fast-track review designation for CINP [sec_mda · as of 2026-08-14].
- Phase 2b interim data showed Halneuron treatment effect versus placebo with a low dropout rate of 4.5% [sec_mda · as of 2026-05-15].
- SP16, a proprietary peptide, has shown neuroprotective effects in preclinical research and is entering Phase 1 [sec_mda · as of 2026-08-14].
- Announced a worldwide development and commercialization partnership for legacy antiviral assets with potential value up to $100M [news · published 2026-08-13].
What to weigh
- Company is pre-revenue and development-stage, with no approved products [sec_mda · as of 2026-08-14].
- Net loss of -$11.5M for the period ending 2026-06-30 [sec].
- Cash & equivalents of $9.6M as of 2026-06-30 may be limited for ongoing clinical programs [sec].
- Halneuron® Phase 2b results are not yet available; clinical and regulatory risks remain [news · published 2026-09-14].
From the filings
Quoted directly from source documents.
Company is pre-revenue and development-stage
“We are a pre-revenue, development-stage biopharmaceutical company focused on developing new medicines to treat pain and peripheral neuropathy associated with cancer treatment”
SEC MD&A · August 14, 2026
Halneuron® has FDA fast-track designation
“Halneuron®has been granted FDA fast-track review designation by FDA as a treatment for CINP.”
SEC MD&A · August 14, 2026
Phase 2b enrollment completed with 239 patients
“Enrollment of 239 Patients Meets Upper End of Planned Enrollment Target Range”
News · September 14, 2026
Top-line data expected November 2026
“Topline Data Expected in November 2026”
News · September 14, 2026
Risks & what to watch (4)›
Key risks
- Pre-revenue status — No approved products or revenue; company relies on funding and partnerships [sec_mda · as of 2026-08-14].
- Clinical trial risk
- Cash runway — Cash & equivalents $9.6M as of 2026-06-30 may be insufficient for all programs [sec].
- Regulatory uncertainty — SP16 has not yet completed Phase 1; regulatory path uncertain [sec_mda · as of 2026-08-14].
What to watch
- Top-line data from Halneuron® Phase 2b trial expected November 2026 [news · published 2026-09-14].
- Initiation of SP16 Phase 1 trial for CIPN [sec_mda · as of 2026-08-14].
- Progress of the worldwide development and commercialization partnership for legacy antiviral assets [news · published 2026-08-13].
- Financial updates and cash position in future quarterly reports [sec].
Sources: News · SEC MD&A · Generated September 27, 2026 · How we verify sources →
Run Dogwood Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Dogwood Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.18 · 0% dilution
Lead: Phase 3
4 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
13
Total value held
$7.6M
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 3,280,000 | $6.9M |
| vanguard capital management llc | 132,154 | $279K |
| geode capital management, llc | 79,434 | $168K |
| vanguard fiduciary trust co | 62,736 | $132K |
| northern trust corp | 23,779 | $50K |
| goldman sachs group inc | 14,598 | $31K |
| marshall wace, llp | 11,756 | $25K |
| tower research capital llc (trc) | 8,067 | $17K |
| ubs group ag | 7,085 | $15K |
| activest wealth management | 120 | $253 |
Showing top 10 of 13 institutional holders of Dogwood Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 20, 2026- % of float
- 0.6%
- Days to cover
- 0.9
- Shares short
- 70,605
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
DWTX short interestGovernance
Frequently asked questions
What is the AI investment thesis for Dogwood Therapeutics, Inc.?
Dogwood Therapeutics (DWTX) is a pre-revenue, development-stage biopharmaceutical company focused on developing non-opioid medicines for pain and peripheral neuropathy associated with cancer treatment, with lead asset Halneuron® in Phase 2b and SP16 entering Phase 1.
What is Dogwood Therapeutics, Inc.'s lead drug candidate?
Dogwood Therapeutics, Inc.'s most advanced tracked candidate is halneuron (Phase 2) for Chemotherapy Induced Neuropathic Pain.
Who is the CEO of Dogwood Therapeutics, Inc.?
Mr. Gregory Duncan is the chief executive officer of Dogwood Therapeutics, Inc. (DWTX).
Where is Dogwood Therapeutics, Inc. headquartered?
Dogwood Therapeutics, Inc. (DWTX) is headquartered in Alpharetta, GA, United States.
What therapeutic areas does Dogwood Therapeutics, Inc. focus on?
Dogwood Therapeutics, Inc. develops therapies across Neurology, Infectious Disease, Pain.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.